AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Feb 26, 2019
31580_dirs_2019-02-26_18f525c0-0941-4f8a-b674-7cf3ce36216c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-02-22
Reporting Person: Biller Scott (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-02-22 | Stock option (right to buy) | $58.86 | A | 40000 | Acquired | 2029-02-22 | Common stock (40000) | Direct |
| 2019-02-22 | Restricted stock units | $ | A | 10000 | Acquired | Common stock (10000) | Direct |
Footnotes
F1: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.